QLD company receives accreditation for 15-minute COVID-19 rapid test in Europe
Queensland-based AnteoTech has received European accreditation for its 15-minute COVID-19 rapid test, to take the fight on the illness overseas. Their innovative, point-of-care COVID-19 antigen rapid test platform, EuGeni now has Conformitè Europëenne Mark registration, meaning it meets the health and safety rules in both the UK and Europe. The company will now start to commercialise their product in Australia, with the test based on their proprietary binding technology paired with global advancements in assay detection systems. The next step is gaining approval from the TGA in Australia to start the manufacturing process. | https://www.anteotech.com/announcements/test-platform-and-covid-19-test-receive-ce-mark-approval/
The Patient Orator® solution is designed to break down barriers making it difficult for patients to communicate with healthcare providers and improve access to basic health care resources. The approach is collaborative. The patient, caregivers, their social support team/care management team, and medical providers focus on hearing the voice of the patient to help them in their health and wellness journey.You can subscribe to be notified of the app release www.patientorator.com
Researchers at The University of Queensland will progress toward a trial to see if a specialised dietary fibre supplement is safe for use in children with type 1 diabetes after positive results in adults. With the increase of type I diabetes in the last 50 years, growing evidence is showing that changes in gut bacteria may hold a secret to the triggering of the disease. By targeting the gut microbiome with specialised dietary fibre supplements, researchers hope to see a low-cost approach to prevention and glucose management. | https://medicine.uq.edu.au/article/2021/07/diabetes-research-challenging-paramount
Researchers at the University of Queensland and WEHI have identified a new generation anti-cancer drug that could be repurposed for aggressive childhood brain tumour, medulloblastoma. The international collaboration spent five years mapping the genetics of this common and fatal brain cancer for children. The existing drug has been approved for other diseases or cancers but never tested in paediatric brain tumours. Ixabepilone which is used to treat breast cancer, was found to block tumour growth and significantly extend survival rates in preclinical models. | https://www.uq.edu.au/news/node/129501
Lynn Wood
Madeline Cunningham